Anti-cyclic citrullinated peptide antibody-positive rheumatoid arthritis caused by bacterial organizing pneumonia in a patient with Sjogren’s syndrome-Reference-Cited by-同舟云学术

Anti-cyclic citrullinated peptide antibody-positive rheumatoid arthritis caused by bacterial organizing pneumonia in a patient with Sjogren’s syndrome

Published:2022-06-01 Issue:2 Volume:60 Page:127-131
ISSN:2501-062X
Container-title:Romanian Journal of Internal Medicine
language:en
Short-container-title:

Author:

Horino Taro¹,Yoshida Mitsuharu¹,Inotani Satoshi¹,Anabuki Kazuki²,Ohnishi Hiroshi²,Komori Masahiro³,Ichii Osamu⁴,Terada Yoshio¹

Affiliation:

1. Department of Endocrinology, Metabolism and Nephrology , Kochi Medical School, Kochi University , Japan

2. Department of Hematology and Respiratory Medicine , Kochi Medical School, Kochi University , Japan

3. Department of Otolaryngology , Kochi Medical School, Kochi University , Japan

4. Laboratory of Anatomy , Department of Biomedical Sciences, Graduate School of Veterinary Medicine , Hokkaido University , Japan

Abstract

Abstract A 58-year-old woman with a history of Sjogren’s syndrome was admitted to our hospital with cough, decreased right lung breath sounds and arthralgia in both thumbs. Chest computed tomography showed consolidation with air bronchogram in the right lung. Levels of anti-cyclic citrullinated peptide antibody and rheumatoid factor levels were significantly elevated. She was diagnosed with rheumatoid arthritis induced by bacterial organizing pneumonia. Treatment with salazosulfapyridine was added for rheumatoid arthritis and arthralgia gradually improved. This case highlights that respiratory infections could lead to anti-cyclic citrullinated peptide antibody-positive rheumatoid arthritis in patients with Sjogren’s syndrome.

Publisher

Walter de Gruyter GmbH

Link

https://www.sciendo.com/pdf/10.2478/rjim-2022-0003

Reference21 articles.

1. 1. VITALI C., BOMBARDIERI S., JONSSON R., MOUTSOPOULOS HM., ALEXANDER EL., CARSONS SE., et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.10.1136/ard.61.6.554175413712006334

2. 2. ALANI H., HENTY JR., THOMPSON NL., JURY E., CIURTIN C. Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sjögren’s syndrome (secondary Sjögren’s syndrome) focusing on autoimmune rheumatic diseases. Scand J Rheumatol. 2018;47(2):141–54.10.1080/03009742.2017.132490928927315

3. 3. BROWN LE., FRITS ML., IANNACCONE CK., WEINBLATT ME., SHADICK NA., LIAO KP. Clinical characteristics of RA patients with secondary SS and association with joint damage. Rheumatology (Oxford). 2015;54(5):816–20.10.1093/rheumatology/keu400441608325313147

4. 4. KIM SM., PARK E., LEE JH., LEE SH., KIM HR. The clinical significance of anti-cyclic citrullinated peptide antibody in primary Sjögren syndrome. Rheumatol Int. 2012;32(12):3963–7.10.1007/s00296-011-2274-322205381

5. 5. LEE J., KOH JH., KIM JW., SUNG YK., LEE SS., CHOE JY., et al. Performance of the 2016 ACR-EULAR classification criteria for primary Sjogren’s syndrome in a Korean cohort. Rheumatol Int. 2018;38(9):1651–60.10.1007/s00296-018-4109-y30030624